 |
|
|
| |
Changes outside integrase in a patient failing on dolutegravir
maintenance monotherapy points to a new resistance mechanism
|
| |
| |
POSTER PDF ATTACHED TO VIEW LARGE GRAPHS IN REAL SIZE
Download the PDF here
Reported by Jules Levin
EACS - 16th European AIDS Conference, October 25-27, 2017. Milan
C. Lungu 1, P.H.M. Boers 1, I.E.A. Wijting 2, B.J.A. Rijnders 2, D.A.M.C. van de Vijver , S.D. Pas 1, C.A.B. Boucher 1, J.J.A. van Kampen1 , R.A. Gruters 1
1Department of Viroscience, Erasmus University Medical Centre, Rotterdam, Netherlands,
2Department of Internal Medicine and Infectious Diseases Erasmus University Medical Centre, Rotterdam, Netherlands
References
Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin A, Perno C. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev. 2010;11:17-29
Dicker IB, Samanta HK, Li Z, Hong Y, Tian Y, Banville J, et al. Changes to the HIV long terminal repeat and to HIV integrase dierentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors. J Biol Chem.
2007;282:31186-96.Z
Malet I, Subra F, Charpentier C, Collin G, Descamps D, Calvez V, Marcelin A, Delelis O. 2017. Mutations located outside the integrase gene can confer resistance to HIV-1 integrase strand transfer inhibitors. mBio 8:e00922-17
|
| |
|
|
|
|
|
